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Abstract
Introduction: Despite the rollout of antiretroviral therapy (ART), challenges remain in ensuring timely access to care and
treatment for people living with HIV. As part of a multi-country study to investigate HIV mortality, we conducted health
facility surveys within 10 health and demographic surveillance system sites across six countries in Eastern and Southern
Africa to investigate clinic-level factors influencing (i) use of HIV testing services, (ii) use of HIV care and treatment and (iii)
patient retention on ART.
Methods: Health facilities (n = 156) were sampled within 10 surveillance sites: Nairobi and Kisumu (Kenya), Karonga
(Malawi), Agincourt and uMkhanyakude (South Africa), Ifakara and Kisesa (Tanzania), Kyamulibwa and Rakai (Uganda)
and Manicaland (Zimbabwe). Structured questionnaires were administered to in-charge staff members of HIV testing,
prevention of mother-to-child transmission (PMTCT) and ART units within the facilities. Forty-one indicators influen-
cing uptake and patient retention along the continuum of HIV care were compared across sites using descriptive
statistics.
Results: The number of facilities surveyed ranged from six in Malawi to 36 in Zimbabwe. Eighty percent were government-
run; 73% were lower-level facilities and 17% were district/referral hospitals. Client load varied widely, from less than one up
to 65 HIV testing clients per provider per week. Most facilities (>80%) delivered services or interventions that would support
patient retention in care such as delivering free services, offering PMTCT within antenatal care, pre-ART monitoring and
adherence counselling. Many facilities under-delivered in several areas, however, such as targeted testing for high-risk groups
(21%) and mobile testing (36%). There were also intra-site and inter-site differences, including in the delivery of Option B+
(ranging from 6% in Kisumu to 93% in Kyamulibwa), and nurse-led ART initiation (ranging from 50% in Kisesa to 100% in
Karonga and Agincourt). Only facilities in Malawi did not require additional lab tests for ART initiation. Stock-outs of HIV test
kits and antiretroviral drugs were particularly common in Tanzania.
Conclusions: We identified a high standard of health facility performance in delivering strategies that may support
progression through the continuum of HIV care. HIV testing policy and practice was particularly weak. Inter- and intra-
country differences in quality and coverage represent opportunities to improve the delivery of comprehensive services to
people living with HIV.
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Introduction
In 2015 in Eastern and Southern Africa, 10.3 million peo-
ple were accessing antiretroviral therapy (ART), represent-
ing an estimated 54% [50–58%] of all people living with
HIV (PLHIV) in the region [1]. Ambitious HIV programmes
have resulted in substantial declines in mortality rates
among HIV-infected adults, estimated at 58% since the
initial expansion of ART in a recent community level
cohort analysis in six countries in Eastern and Southern
Africa [2].
A large body of evidence, however, indicates that ser-
vices are inadequately promoting access to testing or pro-
gression onto treatment for those diagnosed positive. A
2012 systematic review and meta-analysis in sub-Saharan
Africa found that, on average, 39% of PLHIV were tested
and knew their status; 57% of those diagnosed positive
underwent assessment of ART eligibility and fewer (51%)
returned for the result; among the newly diagnosed,
41–64% were found to be eligible for ART (depending on
initiation criteria), among whom only 66% started ART;
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among those not yet eligible, a median of 45% remained in
pre-ART care [3]. Another systematic review of 39 patient
cohorts in the region found average retention on ART of
65% at three years [4]. Differences in progression through
this “cascade” between or within countries are likely to
impact on country-level variations in mortality among
PLHIV.
While engagement of PLHIV with services and subse-
quent progression through the cascade may stem from
broader socio-economic, cultural or political influences,
HIV service coverage and quality play a critical role [5].
Several systematic reviews have identified a range of health
service influences on engagement of PLHIV with care,
including attributes of service access and coverage; the
quality of service provision; the coordination of care and
follow-up; support given to PLHIV; and the clinical manage-
ment of patients [6–9]. We subsequently incorporated
these factors into a conceptual framework (Figure 1) to
guide a broader study of policy and programmatic influ-
ences on cascade progression and adult HIV-related mor-
tality in sub-Saharan Africa, conducted through the network
for Analysing Longitudinal Population HIV/AIDS data in
Africa (ALPHA, http://alpha.lshtm.ac.uk/).
We previously used this framework to review national
adult HIV policies across the six sub-Saharan countries with
generalized HIV epidemics where ALPHA collects mortality
data [10]. We found that while policies were consistent in
many areas (e.g. guarantees of free HIV services, promotion
of opt-out HIV testing, regular pre-ART CD4 monitoring,
task-shifting for ART initiation and integrated service pro-
motion), there were also wide variations (e.g. targeted
testing of high-risk groups, referral to peer support or
home-based care, requirements of laboratory testing
before ART initiation). The variation was surprising since
many national programmes often follow standardized WHO
recommendations [10].
Here we build on the policy review by investigating and
comparing health facility practices that may influence
access of PLHIV to adult HIV services within the 10 health
and demographic surveillance system (HDSS) sites in
Eastern and Southern Africa participating in the larger
ALPHA mortality study: Kisumu (KEMRI/CDC) and Nairobi
(Korogocho and Viwandani settlements) (both Kenya);
Karonga (Malawi); Agincourt and uMkhanyakude (South
Africa); Ifakara and Kisesa (Tanzania); Kyamulibwa and
Rakai (Uganda); and Manicaland (Zimbabwe). As countries
in the region adopt UNAIDS “90-90-90” targets and “test
and treat” policies, it is important to identify areas of
strength and weakness in HIV service provision across the
continuum of care.
Figure 1. Conceptual framework identifying health system factors influencing access to adult HIV services through the cascade.
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Methods
Study settings
Study sites were located in Eastern and Southern Africa
(Figure 2), and key characteristics are highlighted in
Table 1. More detailed information has been provided by
Reniers et al. [2].
Sampling of health facilities within sites
Health facilities providing HIV services to their HDSS
population were surveyed, including government-,
NGO-, and privately-run facilities (including inside, on
the border of, or just outside surveillance areas). All
facilities provided HIV testing and counselling (HTC),
most provided prevention of mother-to-child transmis-
sion (PMTCT) and/or ART services. In some, a sample of
facilities was surveyed: in Nairobi, a convenience sample
was taken to include different types or levels of health
facility used by HDSS residents; in Ifakara, only facilities
with a patient load ≥100/month were surveyed
(Table 1).
Table 1. Study setting and sampling information for the facility surveys, by site
Country HDSS site
Size of HDSS site
(km2)
Population
of HDSS
site
HIV
prevalence
No. of
facilities
surveyed/
total no.
facilities in
HDSS*
No.
facilities
outside
HDSS site
surveyed* Sampling strategy
Kenya Nairobi Korogocho: 0.97 km2
Viwandani: 0.5 km2
72,557 12% 10/0 10 No HIV facilities in HDSS.
Convenience sample of
different types of HIV
facilities used by residents:
five on edge of HDSS, the
remainder 2–15 km away
Kisumu (KEMRI/
CDC)
369 km2 141,956 15% 34/34 0 All facilities
Malawi Karonga 135 km2 39,045 7% 6/7 1 All facilities, except one small
private clinic
South Africa Agincourt 420 km2 90,000 19% 9/10 2 All facilities, except one
public–private health
centre
uMkhanyakude 438 km2 90,000 33% 17/7 10 All facilities, along with 10
facilities in the wider
district also supported by
the HDSS management
Tanzania Ifkakara 2400 km2 169,000 7% 12/19 7 All facilities with ≥100
patients per month,
including seven outside the
HDSS used by residents
Kisesa 150 km2 30,486 7% 8/5 3 All facilities, including three
referral hospitals outside
HDSS site
Uganda Rakai 320 km2 32,109 13% 14/17 0 All facilities supported by
Rakai Health Sciences
Program
Kyamulibwa 54.3 km2 21,450 9% 9/3 6 All facilities, including facilities
outside HDSS used by
residents
Zimbabwe Manicaland 36,459 km2 11,139 15% 36/95 2 All main hospitals (five) plus
random sample of clinics
used by HDSS residents,
plus two facilities outside
HDSS used by residents
*Facilities on the border with or outside the HDSS site were included if they were commonly used by residents of the sites.
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Data collection, processing and analysis
The questionnaire was developed by reviewing existing HIV
health facility surveys, including the World Health
Organization Service Availability and Readiness Assessment
surveys, and an instrument from Manicaland developed by
Imperial College London [11]. Indicator selection was based
on the conceptual framework shown in Figure 1.
The questionnaire covered health facility characteristics
and staffing, and HTC, PMTCT and ART service provision
practices. These included indicators related to the five
themes in the conceptual framework and the policy review:
(i) service access and coverage; (ii) quality of care; (iii)
coordination of care and patient tracking; (iv) support to
PLHIV; and (v) medical management.
The questionnaire was administered in English to the
staff manager at each facility or within relevant sub-units.
Interviewers observed the availability of treatment guide-
lines and consulted pharmacy records for patient numbers,
drug stocks and test availability. Data collection took place
between July 2013 and January 2015. Data from eight sites
were entered centrally into the MS SQL Server (Microsoft
Corp). Data were cleaned, merged and exported for analy-
sis using Stata 12 (Stata Corp). Two sites, Kisumu and
Manicaland, entered their own data which were subse-
quently merged into the pooled data set. Missing data are
indicated in the tables and denominators adjusted.
For each site, service provision is presented using
descriptive statistics. For continuous data, the median and
range from facilities within each site are shown; for cate-
gorical variables, the number and proportion of facilities
are shown. Since most sites included all facilities in opera-
tion, no formal statistical comparisons between sites have
been made. Bar charts were produced to examine the
distribution of a selection of key indicators of interest
within the four service areas across the 10 sites.
Ethics
Ethical approval was received from each site from a local
regulatory authority, and from the London School of
Hygiene and Tropical Medicine ethics committee (no.
8891-1). The ALPHA network data sharing agreement cov-
ered data sharing between sites.
Results
One hundred and fifty-six health facilities in the 10 sites
participated in the analysis, ranging from six in Karonga to
36 in Manicaland (Table 2). Health facilities surveyed were
either large health centres or hospitals (27%) or smaller
health centres, clinics or dispensaries (73%) (Figure 3).
South African sites had the highest proportion of small
clinics (89% in Agincourt, 94% in UmKhanyakude).
Clinic overview and staffing
Facility characteristics are presented in Table 2. Most facilities
were government-run (80%). All provided HIV testing, 97%
Figure 2. Location of the ALPHA Network member study sites.
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provided PMTCT services, 94% provided HIV care, 88% pro-
vided ART and 52% provided laboratory services. Client flow
varied by clinic type (data not shown) and site: median HIV
testing clients averaged <20 per week in Ifakara, Kyamulibwa
and Manicaland, but reached 78 in Nairobi. There was less
variation in client load between sites (weekly HTC clients per
provider ranging between 1.3 in Nairobi and Karonga to 6.9 in
Rakai) than within sites (ranging between 0.2 and 65 HTC
clients per week in Kisesa; and 5–254 ART clients per week in
Rakai). Annual staff turnover varied widely from 0% in
Kisumu, Ifakara and Manicaland to 67% in uMkhanyakude.
Influences on access to HIV testing
Influences on access to HIV testing are presented in Table 3
and Figure 4a. HTC was freely available in most facilities,
but provider-initiated testing and counselling (PITC) in ante-
natal care (ANC) was not universal in Kisumu, Karonga,
Kyamulibwa, Rakai and Manicaland. Very few facilities
explicitly offered HTC to high-risk groups and most did not
offer mobile outreach.
Quality of care factors influencing HTC included availability
of national guidelines, found in all facilities in Karonga,
Agincourt, uMkhanyakude and Manicaland; regular staff
training, which was only conducted in all facilities in Malawi;
and regular quality audits, which were conducted nearly
everywhere. Stock-outs of testing kits occurred most rarely
in Agincourt and Rakai. Repeat testing after the window
period was commonly conducted, but less so during preg-
nancy. Most facilities (89%) checked whether PLHIV ultimately
registered in care, although this was lower in Karonga (60%).
Provision of pre-test counselling was generally common,
although only universal in Nairobi, Agincourt and
uMhkanyakude, and infrequent in Kisesa (29%).
Influences on access to HIV treatment in PMTCT
Factors influencing access to HIV treatment were investi-
gated in PMTCT units (n = 151) (Table 4 and Figure 4b). Free
PMTCT services were provided everywhere except Nairobi
(70%), Kyamulibwa (75%) and Manicaland (43%). Most
facilities had well-stocked maternal PMTCT drugs (average
89%), but only 58% of Ifakara and 33% of Kisesa facilities
were well-stocked.
Regarding PMTCT coordination and integration, anti-ret-
roviral prophylaxis for PMTCT was given on the same day as
ANC services in most facilities (88%), and HIV-positive
mothers were commonly referred for ART within one
month of delivery (89%). Only half (53%) recorded referral
in patient-retained cards, and fewer gave PMTCT drugs in
advance for home or elsewhere delivery (50%). In facilities
where ART was provided in a different building or unit
(n = 131), most sites checked the woman’s arrival for
treatment (96%). There was wide inter-site variation in
referrals accompanied by health workers (91% in Kisumu
versus none in Manicaland).
The “Option B+” regimen (commencement of life-long
treatment during pregnancy) was offered in 42% of facil-
ities, but most common in Karonga (80%), uMkhanyakude
(88%), Kyamulibwa (88%) and Rakai (93%).
Access to HIV treatment
Factors influencing access to HIV treatment were assessed
within HIV care units (n = 147) (Table 5 and Figure 4c).
Although some facilities in Kyamulibwa (40%) and
Manicaland (13%) charged some kind of fee (e.g. admis-
sion), ART was free in most facilities. ART initiation was
available everywhere except Manicaland (61% only
Figure 3. Type of facilities surveyed, by site*.
*Small clinic/dispensary: see only outpatients. Large clinic/small health centre: have limited no of beds (for maternal deliveries) and may be
headed by clinical officer/medical officer. Large health centre/sub-district hospital: have capacity for inpatients. Referral hospital: district,
provincial or national hospital receiving referrals from smaller hospitals.
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Figure 4. Selected factors influencing access to HIV services.
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provided refills). Nurse-led ART initiation was widespread
(78%), except in Nairobi and Kisesa (50%).
Only 71% of clinics recorded pre-ART visits on patient-
retained cards, with low proportions in Nairobi (50%),
Karonga (40%) and Agincourt (33%). Co-trimoxazole prophy-
laxis (CTX) was in stock in only 50% Ifakara’s facilities and
75% of Kisesa’s, but otherwise available. There were differ-
ences in ART initiation among TB-infected PLHIV, with no
facilities allowing rapid initiation (same day/within two
weeks) in Nairobi, Agincourt, uMkhanyakude and Kisesa, vs.
80% in Karonga. Few facilities conducted ART eligibility
assessment with clinical staging only. Most sites initiated
treatment with a CD4 count of ≤350 cells/mm3, except
uMkhanyakude where 41% initiated ≤500 cells/mm3. Some
still initiated at ≤250 cells/mm3 (78% Agincourt, 58% Ifakara
and one facility in each of Kisumu, Kisesa, Masaka and Rakai)
(data not shown). Only 20% facilities required no additional
laboratory tests before treatment initiation, except Malawi
where none required them. A few clinics in Agincourt,
Kyamulibwa and Rakai allowed patients to initiate at first
contact with the clinic. More facilities (44%) used WHO’s
2013 first line ART regimen (containing tenofovir), compared
to 33% using WHO’s 2010 regimen, and this was most
common in Malawi and South Africa.
Adherence counselling was compulsory everywhere
except one clinic in Agincourt and Rakai, and seven in
uMkhanyakude.
Retention on HIV treatment
Factors influencing retention were assessed within facilities
providing ART (n = 126) (Table 6 and Figure 4d). National
treatment guidelines were mostly available, though less so
in Karonga (60%) and Manicaland (40%). Most staff under-
went recent ART training, though less commonly in Ifakara
(25%) and Manicaland (40%). Well-stocked facilities were
common, but infrequent in Tanzania: 8.3% in Ifakara, none
in Kisesa with opportunistic infection drugs; 75% in Ifakara,
50% in Kisesa with ART drugs.
Two-thirds of facilities conducted at least six-monthly
CD4 count monitoring, but this was low in Agincourt
(11%), uMkhanyakude (12%) and Rakai (14%). About 41%
of facilities gave three-monthly supplies of drugs but 94%
allowed drug collection by a designee. Pill counts at every
visit were common (74%) but infrequent in uMkhanyakude
(35%). While few sites (21%) conducted home visits follow-
ing poor adherence, most did so after a missed appoint-
ment (90%), although not in Ifakara (42%).
Nearly all facilities required more than one adherence
counselling session (93%), but not in uMhkanyakude (56%).
Many (65%) offered individual counselling but this was low
in Kisumu (3%) and Kisesa (25%). Support groups were
generally available, although offered by only half of facil-
ities in uMkhanyakude and Kyamulibwa.
Prophylactic Isoniazid Preventive Therapy (IPT) for TB
prevention was offered and in-stock in under half of facil-
ities, and not available anywhere in Ifakara, Kyamulibwa,
Rakai or Manicaland. TB screening was conducted at every
visit in most facilities (94%).
Discussion
This study provides a detailed picture of HIV service delivery in
156 facilities in six sub-Saharan countries, highlighting substan-
tial variation within and between countries in programme-
level indicators influencing HIV service uptake and retention
in care. Comparative multi-country surveys of HIV service
delivery quality have been limited, but have also shown sub-
stantial variation between settings [12]. And while a recent
meta-analysis and review have both demonstrated the critical
role that health services play in influencing retention in care
[13,14], to our knowledge this is the first study across the
Eastern and Southern African region comparing facility perfor-
mance over the whole continuum of HIV care, including influ-
ences on testing uptake, initiation of, and retention on ART.
The assessment of service performance using a standardized
instrument across the 10 sites is useful both for programme
monitoring and for benchmarking performance between set-
tings and over time. The HDSS that form the ALPHA Network
provide important demographic parameters for national pol-
icy-makers [2,15], and this survey provides critical contextual
information to help explain differences in HIV service access by
the local populations, and ultimately differences in HIV-related
mortality through the HIV treatment cascade.
Many of the facilities we surveyed performed well across
multiple indicators that may be expected to impact positively
on service utilization. The near-universality of free HIV services,
high levels of PMTCT provision within ANC, pre-ART monitor-
ing availability and adherence counselling were impressive,
demonstrating the remarkable progress made in the provision
of HIV care in the region since the commencement of ART
rollout. However, several areas were identified with inconsis-
tency in service provision across the continuum of care.
Differences within or between sites and countries indicate
areas of opportunity for increasing patient engagement.
There were common service gaps influencing HIV testing
access. The high testing volume in some facilities was worry-
ing, as well as frequently reported test kit stock-outs. Poor
quality testing may undermine uptake and/or the feasibility of
annual testing, recommended by WHO [16]. Furthermore, a
growing body of evidence indicates the importance of com-
munity-based testing approaches, including mobile outreach
[13,17,18], approaches often absent in facilities surveyed.
High-risk groups were only targeted in Nairobi, suggesting an
“invisibility” in the other predominantly rural locations sur-
veyed. It was also particularly alarming that, with the excep-
tion of South Africa, pre- and post-testing counselling services
were not consistently provided anywhere. This has implica-
tions on ascertainment of consent, patient understanding,
provision of psychosocial support and linkage to care.
Findings also indicated weaknesses in service coordina-
tion and patient tracking, which may be particularly influ-
ential on high rates of attrition across the HIV cascade
documented in multiple sub-Saharan settings [6,8,9].
Effective referral must be strengthened if linkage to HIV
treatment is to be improved.
The starkest differences between sites were in factors
likely to influence access to ART, with Malawian facilities
performing particularly well across a range of indicators in
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this area, including nurse-led ART initiation, ART initiation
without laboratory testing and PITC for pregnant women
with PMTCT Option B+ for those testing positive. Malawi
often stands out for its progressive HIV policies [10], despite
being one of the poorest African countries, and our findings
suggest that policies are translating into practice, even in
rural areas. Other sites, notably those in Kenya, performed
less well across the same indicators, despite having a sub-
stantially higher per capita HIV budget and health worker
ratios [19]. The impact of rapid initiation policies on long-
term adherence, however, remains under-studied.
All sites exceled in some areas, but lagged in others. For
example, many facilities in Tanzanian sites reported regular
drug or supply stock-outs, likely to impact negatively on
patient progression and clinical outcomes, but generally per-
formed well in supporting PLHIV on ART, likely impacting
positively on retention and adherence. Multiple instances of
variation within countries were observed where two sites
were studied (Uganda, Kenya, South Africa,Tanzania) suggest-
ing that national HIV policy differences only partly explain
variation in service provision. For example, in Kenya, nurse-
led ART initiation was very common in Kisumu but implemen-
ted only in half of Nairobi facilities, despite national policy
[10]. In Tanzania, rapid ART initiation for TB+ was allowed in
most facilities in Ifakara, but none in Kisesa.
The causes of variation in service performance between sites
and across countries are likely to be multi-faceted, and may
include national policy variation (although some policies com-
mon to all six countries, such as repeat HIV testing in pregnancy,
or pill counts at every visit, were not always implemented in
practice), the complexity of the policy and its ease of imple-
mentation, the programmatic support to ensure providers are
trained and practicing it, and a wide range of structural factors
influencing quality of care, such as provider remuneration and
motivation, training, drugs/supplies procurement processes,
and supervision and management [20,21]. Further research is
planned by the ALPHA Network to investigate the extent to
which the observed service delivery reflects national policy
differences; the local factors influencing policy implementation;
and the association between policy implementation, cascade
progression and mortality. Research is also being undertaken
within the HDSS to explore health-seeking behaviour, to under-
stand the normative and social drivers of service utilization
across the continuum of HIV care.
Limitations
The survey was designed to be representative of HDSS
service provision, thus national representation should not
be implied. However, most facilities surveyed are consid-
ered typical of national service provision, except three large
facilities in Rakai, Masaka and Kisumu. These sites received
additional support and thus quality observed may have
been higher than average. However, there may be differ-
ences in treatment-seeking behaviour in these HDSS due to
regular population-based HIV testing, leading to higher
volumes of patients than might otherwise be expected.
The completion of the survey by facility managers pre-
sents a potential reporting bias, and results may not reflect
the reality of care quality received by patients. The study
dates (with fieldwork conducted in 2013/2014) should also
be considered in interpreting findings; important interna-
tional policies such as Option B+ had only been recom-
mended by WHO in June 2013, and were not expected to
be widely implemented at the time of the study. Lastly,
while the survey design and conceptual framework were
guided by a literature review and aimed to be comprehen-
sive, certain indicators impacting on access to HIV care may
have been missed, in part due to the rapidly evolving field.
Future research should consider capturing the ART moni-
toring strategy used (e.g. whether routine viral load mon-
itoring offered; or availability of point-of-care CD4 testing);
partner testing in ANC; the number of pre-ART counselling
sessions required; or actions taken when PLHIV do not
register in care post-referral.
Conclusions
This study identified an overall high standard of HIV
service delivery performance across six countries in
sub-Saharan Africa, but with substantial variability in
service indicators expected to impact on uptake of the
continuum of HIV care. Inter- and intra-country differ-
ences represent opportunities to improve the delivery of
comprehensive services to PLHIV. Patient engagement
across this continuum is likely to remain sub-optimal
unless issues relating to service access, quality of care
and coordination are consistently improved in practice.
Policy-makers must act on the weaknesses identified, in
particular poor performance on testing accessibility, as
well as deficiencies in coordination of care and patient
tracking. Such action will be essential to support imple-
mentation of WHO’s new “test and treat” strategy [10],
since success is contingent upon high levels of HIV
testing, linkage to care and retention following
initiation.
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